MedTrace Logo

Collection of PBMCs From Healthy Subjects for the Development of Cellular Immunotherapy Product

NCT04295096 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2021-06-09

No results posted yet for this study

Summary

Title: Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy Subjects for the Development of Cellular Immunotherapy Product

Background:

CAR-T therapies are being developed that utilize modified immune cells to fight tumors. 'Off-the-shelf' allogeneic CAR-T technology has better efficacy and more promising clinical applications. Investigators want to use the cells of healthy subjects to perform the studies. To accomplish this, they are collecting PBMCs through apheresis.

Objectives:

To collect PBMCs from healthy subjects for product development for cell Immunotherapies.

Conditions

  • Healthy Subject

Interventions

DEVICE

Peripheral blood mononuclear cell apheresis

Peripheral blood mono-nuclear cell donation for tumor immunotherapy study of Universal CAR-T cells

Sponsors & Collaborators

  • Nanjing Legend Biotech Co.

    collaborator INDUSTRY

  • Jun Zhu

    lead OTHER

Principal Investigators

  • Jun Zhu, M.D. · Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2024-02-29
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04295096 on ClinicalTrials.gov